Vanguard S&P 500 ETF (VOO) Daily Update, 1/9/2026
at www.tipranks.com (Fri, 9-Jan 8:31 AM)
SPY ETF Daily Update, 1/9/2026
at www.tipranks.com (Fri, 9-Jan 7:12 AM)
Vanguard S&P 500 ETF (VOO) Daily Update, 1/8/2026
at www.tipranks.com (Thu, 8-Jan 7:59 AM)
Stocks hedge funds love to short
at seekingalpha.com (Thu, 8-Jan 7:57 AM)
SPY ETF Daily Update, 1/8/2026
at www.tipranks.com (Thu, 8-Jan 6:25 AM)
Citi Keeps Their Hold Rating on Moderna (MRNA)
at www.tipranks.com (Wed, 7-Jan 1:26 PM)
Vanguard S&P 500 ETF (VOO) Daily Update, 1/7/2026
at www.tipranks.com (Wed, 7-Jan 8:40 AM)
SPY ETF Daily Update, 1/7/2026
at www.tipranks.com (Wed, 7-Jan 7:03 AM)
“Watch Closely” UBS Downgrades Moderna Stock (MRNA) as Profit Outlook Weakens
at www.tipranks.com (Wed, 7-Jan 2:38 AM)
Moderna downgraded to neutral at UBS on questions over revenue growth
at seekingalpha.com (Tue, 6-Jan 5:32 PM)
S&P 500 notches fresh all-time high with 7,000 now in sight
at seekingalpha.com (Tue, 6-Jan 3:06 PM)
Jefferies Sticks to Their Hold Rating for Moderna (MRNA)
at www.tipranks.com (Tue, 6-Jan 9:06 AM)
Market Chameleon (Mon, 5-Jan 9:07 AM)
Moderna Targets 10% Revenue Growth by 2026 with Expanded Vaccine Pipeline and Streamlined Operations
Market Chameleon (Thu, 20-Nov 7:38 AM)
Market Chameleon (Tue, 18-Nov 8:01 AM)
Moderna Lowers Costs and Narrows Revenue Outlook While Advancing Late-Stage Vaccine Pipeline
Market Chameleon (Thu, 6-Nov 8:04 AM)
Moderna Launches First Patient Study of Multiplexed mRNA T-Cell Engager for Multiple Myeloma
Market Chameleon (Mon, 3-Nov 7:14 AM)
Market Chameleon (Thu, 23-Oct 7:11 AM)
Market Chameleon (Mon, 20-Oct 7:09 AM)
MRNA-4359 Shows Promising 67% Response Rate in PD-L1+ Melanoma: Moderna Highlights Data at ESMO 2025
Market Chameleon (Mon, 13-Oct 7:12 AM)
